Phanes Therapeutics
Leading innovative drug discovery in immuno-oncology
About Phanes Therapeutics
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in immuno-oncology. Currently, it is conducting three Phase 2 clinical trials with spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug and Fast Track designations by the FDA. Our mission is to become a major source of innovation in the biopharma industry. Combining innovative science, disruptive technologies, and revolutionary approaches, we open new possibilities to improve outcomes for patients with cancer. At Phanes, we bring innovation that illuminates the path to cure.
Technology Platforms
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in oncology.
The PACbody® platform enables construction of native IgG-like bispecific antibodies (PACbodies) with drug-like properties. PACbodies are produced without any protein fusion steps, significantly reducing CMC risks. PACbody® has achieved CMC, regulatory and clinical validation.
The SPECpair® platform enhances the manufacturability of bispecific antibodies so that PACbodies can be produced using the conventional mAb manufacturing process. SPECpair® has achieved CMC, regulatory and clinical validation.
The ATACCbody® platform is an extension of PACbody® and SPECpair®, enabling reversible modulation of the anti-CD3 activity of T cell engagers. It’s designed to target solid tumors using immuno-oncology molecules with reduced risk of cytokine release syndrome (CRS).
